Cargando…

A Large London District General Hospital Highlights CLL and Bame As Risk Factors for Severe Disease Amongst Haematology-Oncology Patients

Introduction The earliest documented transmission of the coronavirus SARS-CoV-2, causing the disease Covid-19 occurred in the United Kingdom in February 2020. With data from Wuhan and Italy indicating a significant mortality rate in the region of 1-3% and identification of the risks of co-morbiditie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farmer, Isabel, Babiker, Samah, Okikiolu, Jumoke Stella, Steel, Matthew, Wanniarachchi, Chandima, Littlewood, Shona, Tan, Yishi, Imaeva, Kameta, Duran, Ana, Douvali, Evdoxia, Thanigaikumar, Murugaiyan, Gupta, Sunil, Yeghen, Tullie, Rashid, Sabia, Mir, Naheed, Sahu, Satyajit, Oram, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2020
Materias:	902.Health Services Research-Malignant Conditions (Lymphoid Disease)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330237/ http://dx.doi.org/10.1182/blood-2020-134341

Ejemplares similares

Worldwide Examination of Patients with CLL Hospitalized for COVID-19
por: Roeker, Lindsey E, et al.
Publicado: (2020)

FREQUÊNCI33DE COVID-19 ENTRE PORTADORES DE NEOPLASIAS HEMATOLÓGICAS: RESULTADOS DE PROGRAMA DE TRIAGEM AMPLA NO DECORRER DA PANDEMIA
por: Garnica, M., et al.
Publicado: (2020)

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021)

Immediate COVID-19 treatment in CLL
por: Niemann, Carsten Utoft
Publicado: (2023)

Prediction of clinical outcome in CLL based on recurrent gene mutations, CLL-IPI variables, and (para)clinical data
por: Parviz, Mehdi, et al.
Publicado: (2022)

Prospective Pilot Study of Telehealth As Domiciliary Follow-up after Hematopoietic Cell Transplantation during the COVID19 Pandemic
por: Mussetti, Alberto, et al.
Publicado: (2020)

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)
por: Battiwalla, Minoo, et al.
Publicado: (2020)

Management of Indian Haematology Patients during COVID19 Crisis
por: Subash, Chezhian, et al.
Publicado: (2020)

A Shared Electronic Health Record in a Rural Setting Maintains Hematological Cancer Services Remotely during the COVID-19 Pandemic
por: Cashman, Helen, et al.
Publicado: (2020)

Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients
por: Vijenthira, Abi, et al.
Publicado: (2020)

Treating Acute Leukemia during the COVID-19 Pandemic: A Multicenter Latin American Registry
por: Demichelis, Roberta, et al.
Publicado: (2020)

Outcomes in Patients with Hematological Malignancies Receiving Anti-CD20 Therapy in the Setting of COVID-19 Infection
por: Lopez, Carlos A, et al.
Publicado: (2020)

Mobile-Health Tool to Improve Care of Patients with Hematological Malignancies
por: Sanyal, Amit, et al.
Publicado: (2020)

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
por: Runge, John S., et al.
Publicado: (2020)

COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in CLL: how often is enough?
por: Mellinghoff, Sibylle C., et al.
Publicado: (2022)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
por: Shen, Yandong, et al.
Publicado: (2022)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
por: Thijssen, Rachel, et al.
Publicado: (2022)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations
por: Slot, Matilde, et al.
Publicado: (2023)

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options
por: Malcikova, Jitka, et al.
Publicado: (2021)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL
por: Largeot, Anne, et al.
Publicado: (2023)

COVID-19 Incidence in Asymptomatic Cancer Patients Undergoing Chemotherapy
por: Monteiro, Claudia, et al.
Publicado: (2021)

Online Patient-Reported Platform Detects Trend of Increased COVID-19 Risk and Severity for Multiple Myeloma Patients on Active Lenalidomide-Based Therapy
por: Liu, Emily I., et al.
Publicado: (2021)

Impact of the COVID-19 Pandemic on Primary Care Access for Patients with Hematologic Malignancies
por: Ling, Ying, et al.
Publicado: (2021)

A Prospective Survey to Understand the Preferences and Perspectives of Patients with Hematological Malignancies in a Tertiary Cancer Care Setting in India (CANCOV SURVEY)
por: Sharma, Dr. Neha, et al.
Publicado: (2021)

Virtual Care during the COVID-19 Pandemic Among Patients with Hematologic Malignancies - a Princess Margaret Cancer Centre Experience
por: Suleman, Adam, et al.
Publicado: (2021)

Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States
por: Goyal, Gaurav, et al.
Publicado: (2021)

BAME and COVID-19
por: Mc Crory, P. V.
Publicado: (2020)

The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL
por: Fatima, Narjis, et al.
Publicado: (2021)

Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect(®) CLL Registry
por: Sharman, Jeff P., et al.
Publicado: (2020)

MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis
por: Katsarou, Alexia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_itdqgkn9n29225er50sc6n1j6i